On Tuesday, in the course of current trade, Shares of Johnson & Johnson (NYSE:JNJ), dropped -0.02%, and is now trading at $100.02.
Johnson & Johnson, declared the acceptance of the March 1, 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion. The offer was accepted after consultations with relevant works councils and trade unions. The company anticipates the transaction to close towards the end of 2015, subject to regulatory clearances and other customary closing conditions.
Johnson & Johnson remains dedicated to combating cardiovascular disease through its electrophysiology business, Biosense Webster, in the Medical Devices segment and its leading cardiovascular medicine, XARELTO®, in the Pharmaceutical segment.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
During an Afternoon trade, Shares of AK Steel Holding Corporation (NYSE:AKS), gained 4.62%, and is now trading at $5.43.
AK Steel Holding Corporation, declared plans to introduce one of the first commercially accessible Next-Generation Advanced High Strength Steels in the world. The new technology produces significantly improved formability at higher ultimate tensile strength levels, which provides automotive customers greater opportunities for light-weighting.
The $29 million project comprises modifying the current Hot Dip Galvanizing Line (HDGL) at AK Steel’s Dearborn Works, using new process technology to produce both coated and cold-rolled Next- Generation Advanced High Strength Steels on the same line. Modification of the HDGL is predictable to be accomplished by the Fall of 2016, with new products being shipped to customers by early 2017.
AK Steel Holding Corporation, through its partner, AK Steel Corporation, produces flat-rolled carbon, stainless and electrical steel, and tubular products in the United States and internationally. It produces flat-rolled value-added carbon steels, counting coated, cold-rolled, and hot-rolled carbon steel products; and specialty stainless and electrical steels in sheet and strip forms.
Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII), during its Tuesday’s current trading session fell -1.38%, and is now trading at $0.37.
RXi Pharmaceuticals Corporation, declared that Dr. Pamela Pavco, RXi’s Chief Development Officer, will present at the 23rd World Congress of Dermatology (WCD). This six-day world congress will comprise in-depth presentations by world-class clinicians and/or investigators, dermatology forums for health professionals, patient advocacy and support forums and other plenary sessions.
On Tuesday, June 9, 2015 at 2:35 p.m. PDT, Dr. Pavco will present an overview of the Company’s dermal clinical program with RXI-109. The presentation, entitled “Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids,” will take place during the Free Communications session: FC-07 Wound Healing. The presentation will be accessible on the Company’s website at www.rxipharma.com about one hour after the presentation.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
Finally, Xilinx Inc. (NASDAQ:XLNX), lost -1.14% Tuesday.
Xilinx, declared the 2015.1 release of the SDAccel™ development environment for OpenCL™ framework, C, and C++. The SDAccel development environment is a member of the SDx™ family of development environments for systems and software engineers, enabling up to 25X better performance/watt for data center application acceleration leveraging FPGAs. This new release enhances the SDAccel integrated development environment (IDE), extends OpenCL standard compliance, and features an expanded ecosystem of SDAccel development environment-certified Alliance Members providing platforms, libraries, and design services.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
